Otic Pharmaceuticals appoints Gregory Flesher as chief executive

27 July 2015

Privately-held pharma company Otic, focused on ear, nose and throat disorders, has appointed Gregory Flesher as chief executive and member of the board.

He brings more than 20 years of drug development and commercialization experience, and most recently held the position of chief business officer at Avanir Pharmaceuticals.

Erez Chimovits, chairman of the board of directors for Otic Pharma, said: "We are extremely pleased to have Greg join the company. Greg brings significant depth and breadth of leadership experience in the development and commercialization of new medicines. Under his leadership, he helped build Avanir from a small, single-product company into a leading neuroscience organization with a portfolio of products and more than 500 employees across the United States. Greg's proven ability to successfully build organizations and create shareholder value made him the ideal candidate to lead Otic Pharma."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK